News | June 19, 2023
Alkem Laboratories launches awareness initiative "Stop Sneeze to Wheeze"
Approximately 60 to 78% of individuals diagnosed with Asthma also have concurrent Allergic Rhinitis
Approximately 60 to 78% of individuals diagnosed with Asthma also have concurrent Allergic Rhinitis
Columvi is part of Roche's industry-leading portfolio of T-cell engaging bispecific antibodies in non-Hodgkin lymphoma, which also includes the recently approved Lunsumio to treat follicular lymphoma
Despite nearly 20 years of availability, biosimilars show worldwide adoption rate of only 14% in initiative-tracked countries, while reference medicines still represent 86% of biologic
Cullgen will have the option during the initial stages of clinical development to participate equally in the costs, profits and losses
Thiamine Hydrochloride Injection USP had estimated annual sales of USD 35 million in the U.S.
Convergent action on AMR identified as an important area of intervention
Investment enables development of revolutionary multi-omic platform using super-resolution imaging technology for earlier disease detection and accelerated discovery of therapeutics
Samsung Biologics will provide Pfizer with additional capacity for large-scale manufacturing for a multi-product biosimilars portfolio
The randomised, multi-centre, evaluator blinded, parallel group, active controlled Phase 3 trial is being led by Lanhzou Biotechnique Development
Pfizer is likely to show GSK significant competition
Subscribe To Our Newsletter & Stay Updated
